Richard G. Stock, MD, Author at Grand Rounds in Urology

Richard G. Stock, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Richard G. Stock, MD, is a Professor of Radiation Oncology and Director of Genitourinary Radiation Oncology at the Icahn School of Medicine at Mount Sinai in New York City. He has dedicated his career to delivering the highest quality care to patients using the most advanced technology available, including intensity modulated radiation therapy (IMRT), Novalis Shaped Beam Radiosurgery, real-time ultrasound guided prostate seed implants, and MammoSite, all of which allow him to meticulously target tumors while achieving maximal sparing of normal tissues.

Dr. Stock has served on the board of American College of Radiology Testing and the American Brachytherapy Society, where he is member at large, and as guest editor of a special Brachytherapy issue of Techniques in Urology. He has lectured and presented at dozens of meetings and symposiums across the country and internationally, including in New York, San Francisco, Chicago, Philadelphia, Boston, Spain, Holland, France, and Japan.

Dr. Stock completed his internship at Beth Israel Medical Center and his specialty training at Memorial Sloan-Kettering Cancer Center. He is listed in America's Top Doctors.

Disclosures:

Talks by Richard G. Stock, MD

Panel Discussion: Didactic Session 4: Advances in Radiotherapy

Posted by Richard G. Stock, MD | Aug 2024

Steven J. Frank, MD, FACR, FABS, FASTRO; Richard G. Stock, MD; Nelson N. Stone, MD; Juanita M. Crook, MD, FRCPC

Panel Discussion: Didactic Session 2: Radioprotection

Posted by Richard G. Stock, MD | Aug 2024

Peter F. Orio III, DO, MS; Leonard S. Marks, MD; Richard G. Stock, MD

Adjuvant-Salvage Radiotherapy Following Prostatectomy

Posted by Richard G. Stock, MD | Oct 2023

Richard G. Stock, MD analyzes adjuvant and salvage radiotherapy following prostatectomy in prostate cancer patients with high-risk features or biochemical recurrence post-surgery. Adjuvant radiotherapy is administered shortly after prostatectomy in patients with adverse pathological features, such as positive surgical margins or seminal vesicle invasion, aiming to eradicate microscopic residual disease. Salvage radiotherapy is employed in response to a rising prostate-specific antigen (PSA) level indicating biochemical recurrence after an initial period of undetectable PSA post-surgery.
Dr. Stock reviews pivotal clinical trials and studies, including the SWOG 8794, EORTC 22911, and ARO 96-02 trials, which have demonstrated the efficacy of adjuvant radiotherapy in improving biochemical progression-free survival and overall survival in patients with high-risk features. He highlights the long-term benefits of early intervention with radiotherapy, emphasizing its potential to prevent metastatic progression.

Combining Brachytherapy with SBRT

Posted by Richard G. Stock, MD | Oct 2023

Richard G. Stock explores combining brachytherapy with stereotactic body radiotherapy (SBRT) for prostate cancer treatment.

Combining Therapy with SBRT and Brachytherapy

Posted by Richard G. Stock, MD | Apr 2022

Richard G. Stock, MD, Professor of Radiation Oncology and Director of Genitourinary Radiation Oncology at the Icahn School of Medicine at Mount Sinai in New York City, discusses the efficacy of SBRT and brachytherapy for treating patients with prostate cancer. He explains that combined SBRT and brachytherapy seems to be particularly helpful for intermediate-risk cancer, with studies showing about a 90% biochemical control rate. Dr. Stock then goes over the rationale for combined SBRT and brachytherapy, noting that brachytherapy combined with external beam radiation therapy (EBRT) at standard fractionation demonstrates excellent and safe outcomes for both intermediate- and high-risk prostate cancer, and SBRT appears to be comparable or better than standard fractionation without increased toxicity. He summarizes the findings of several different studies, explaining that with low-dose-rate brachytherapy and SBRT, researchers are seeing very similar results to using standard fractionation with brachytherapy. Dr. Stock also looks at a recent trial with high-dose-rate brachytherapy with SBRT which found a favorable early toxicity profile and encouraging cancer control outcomes. He concludes that the combination of SBRT and brachytherapy is promising, and the initial clinical impression is that patients tolerate the treatment well.